Cochrane · systematic review · CD013864
Antibiotics for hospital‐acquired pneumonia in neonates and children
Korang, SK, Nava, C, Mohana, SP, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
Acute Respiratory InfectionsAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
4
No studies
8
Included studies
NR
No studies 8 · 66.7%Ungraded 0 · 0%Very low 4 · 33.3%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Cefepime compared with ceftazidime for hospital‐acquired pneumonia in neonates and children
Population: neonates and children with hospital‐acquired pneumonia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Maximum Cefepime vs ceftazidime | RR 0.14 [0.01, 2.55] | 1 study · 30 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse events Maximum Cefepime vs ceftazidime | RR 0.14 [0.01, 2.55] | 1 study · 30 participants | Very low Downgraded: risk of bias, imprecision |
Treatment failure Maximum Cefepime vs ceftazidime | RR 0.5 [0.15, 1.64] | 1 study · 30 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Maximum Cefepime vs ceftazidime | no estimate extracted | NR | No studies |
Pneumonia‐related mortality Maximum Cefepime vs ceftazidime | no estimate extracted | NR | No studies |
Non‐serious adverse events Maximum Cefepime vs ceftazidime | no estimate extracted | NR | No studies |
Linezolid compared with vancomycin for hospital‐acquired pneumonia in neonates and children
Population: neonates and children with hospital‐acquired pneumonia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality Maximum Linezolid vs vancomycin | no estimate extracted | NR | No studies |
Serious adverse events Maximum Linezolid vs vancomycin | no estimate extracted | NR | No studies |
Treatment failure Maximum Linezolid vs vancomycin | RR 2.05 [0.49, 8.63] | 1 study · 32 participants | Very low Downgraded: risk of bias, imprecision |
Health‐related quality of life Maximum Linezolid vs vancomycin | no estimate extracted | NR | No studies |
Pneumonia‐related mortality Maximum Linezolid vs vancomycin | no estimate extracted | NR | No studies |
Non‐serious adverse events Maximum Linezolid vs vancomycin | no estimate extracted | NR | No studies |